Literature DB >> 35254594

Purinergic signaling in myocardial ischemia-reperfusion injury.

Yi Zhuang1, Mei-Ling Yu1, Sheng-Feng Lu2,3.   

Abstract

Purines and their derivatives, extensively distributed in the body, act as a class of extracellular signaling molecules via a rich array of receptors, also known as purinoceptors (P1, P2X, and P2Y). They mediate multiple intracellular signal transduction pathways and participate in various physiological and pathological cell behaviors. Since the function in myocardial ischemia-reperfusion injury (MIRI), this review summarized the involvement of purinergic signal transduction in diversified pathological processes, including energy metabolism disorder, oxidative stress injury, calcium overload, inflammatory immune response, platelet aggregation, coronary vascular dysfunction, and cell necrosis and apoptosis. Moreover, increasing evidence suggests that purinergic signaling also mediates the prevention and treatment of MIRI, such as ischemic conditioning, pharmacological intervention, and some other therapies. In conclusion, this review exhibited that purinergic signaling mediates the complex processes of MIRI which shows its promising application and prospecting in the future.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Cardioprotective interventions; Myocardial ischemia–reperfusion injury; Pathological processes; Purinergic signaling

Year:  2022        PMID: 35254594     DOI: 10.1007/s11302-022-09856-4

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  134 in total

1.  The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart.

Authors:  A N Drury; A Szent-Györgyi
Journal:  J Physiol       Date:  1929-11-25       Impact factor: 5.182

Review 2.  Myocardial reperfusion injury.

Authors:  Derek M Yellon; Derek J Hausenloy
Journal:  N Engl J Med       Date:  2007-09-13       Impact factor: 91.245

Review 3.  Cardiovascular adenosine receptors: expression, actions and interactions.

Authors:  John P Headrick; Kevin J Ashton; Roselyn B Rose'meyer; Jason N Peart
Journal:  Pharmacol Ther       Date:  2013-06-10       Impact factor: 12.310

Review 4.  Progression in attenuating myocardial reperfusion injury: an overview.

Authors:  F J P Bernink; L Timmers; A M Beek; M Diamant; S T Roos; A C Van Rossum; Y Appelman
Journal:  Int J Cardiol       Date:  2013-11-12       Impact factor: 4.164

Review 5.  Receptors for purines and pyrimidines.

Authors:  V Ralevic; G Burnstock
Journal:  Pharmacol Rev       Date:  1998-09       Impact factor: 25.468

Review 6.  Purinergic nerves.

Authors:  G Burnstock
Journal:  Pharmacol Rev       Date:  1972-09       Impact factor: 25.468

Review 7.  Targeting of adenosine receptors in ischemia-reperfusion injury.

Authors:  Victor E Laubach; Brent A French; Mark D Okusa
Journal:  Expert Opin Ther Targets       Date:  2010-11-29       Impact factor: 6.902

Review 8.  Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process.

Authors:  A L Moens; M J Claeys; J P Timmermans; C J Vrints
Journal:  Int J Cardiol       Date:  2005-04-20       Impact factor: 4.164

9.  Targeting Myocardial Reperfusion Injury--The Search Continues.

Authors:  Derek J Hausenloy; Derek M Yellon
Journal:  N Engl J Med       Date:  2015-08-30       Impact factor: 91.245

Review 10.  From purines to purinergic signalling: molecular functions and human diseases.

Authors:  Zhao Huang; Na Xie; Peter Illes; Francesco Di Virgilio; Henning Ulrich; Alexey Semyanov; Alexei Verkhratsky; Beata Sperlagh; Shu-Guang Yu; Canhua Huang; Yong Tang
Journal:  Signal Transduct Target Ther       Date:  2021-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.